SEC Comment Letter 0000000000-24-011295 to PSYENCE BIOMEDICAL LTD. (PBM)
PSYENCE BIOMEDICAL LTD.
Date: Oct. 7, 2024 · CIK: 0001985062 · Accession: 0000000000-24-011295
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-282468
Letter
October 7, 2024 Dr. Neil Maresky Chief Executive Officer Psyence Biomedical Ltd. 121 Richmond Street West Penthouse Suite 1300 Toronto, ON MK5 2K1 Re:Psyence Biomedical Ltd. Registration Statement on Form F-1 Filed October 2, 2024 File No. 333-282468 Dear Dr. Neil Maresky: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Daniel Crawford at 202-551-7767 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Ari Edelman, Esq.
Show Raw Text
October 7, 2024
Dr. Neil Maresky
Chief Executive Officer
Psyence Biomedical Ltd.
121 Richmond Street West
Penthouse Suite 1300
Toronto, ON MK5 2K1
Re:Psyence Biomedical Ltd.
Registration Statement on Form F-1
Filed October 2, 2024
File No. 333-282468
Dear Dr. Neil Maresky:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Daniel Crawford at 202-551-7767 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Ari Edelman, Esq.